| FORM 990, PART III, LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS CONTINUED: |
AMP SCZ IS THE FIFTH ACCELERATING MEDICINES PARTNERSHIP INITIATIVE, AND THE FIRST TO FOCUS ON A NEUROPSYCHIATRIC DISORDER. THESE TRAILBLAZING PARTNERSHIPS TRANSFORM THE CURRENT MODEL FOR DEVELOPING NEW DIAGNOSTICS AND TREATMENTS BY BRINGING TOGETHER THE RESOURCES OF NIH AND INDUSTRY TO IMPROVE OUR UNDERSTANDING OF DISEASE PATHWAYS AND FACILITATE BETTER SELECTION OF TARGETS FOR TREATMENT. OTHER AMP INITIATIVES ARE WORKING TO SPEED THE DEVELOPMENT OF NEW DIAGNOSTICS AND TREATMENTS FOR ALZHEIMER'S DISEASE, TYPE 2 DIABETES, RHEUMATOID ARTHRITIS/LUPUS AND PARKINSON'S DISEASE. PLASMA AB ALZHEIMER'S DISEASE IS AMONG THE LEADING CAUSES OF DEATH AMONG U.S. ADULTS. BECAUSE IT GRADUALLY IMPAIRS A PERSON'S THINKING AND SOCIAL SKILLS, ALZHEIMER'S DISEASE ALSO PLACES TREMENDOUS BURDENS ON THOSE LIVING WITH THE DISORDER AS WELL THEIR FAMILIES AND CAREGIVERS. DESPITE DECADES OF RESEARCH, THERE IS NO CURE FOR ALZHEIMER'S DISEASE AND ONLY A HANDFUL OF APPROVED TREATMENTS. THE AVAILABLE TREATMENTS CAN ALLEVIATE THE SYMPTOMS OF DISEASEBUT CANNOT STOP IT FROM CONTINUING TO DAMAGE THE BRAIN. SCIENTISTS ALSO NOW BELIEVE THAT ALZHEIMER'S DISEASE MAY BEGIN DECADES BEFORE OUTWARD SIGNS, SUCH AS MEMORY LOSS, BECOME APPARENT. IN MARCH 2020, THE FNIH BIOMARKERS CONSORTIUM LAUNCHED A BOLD NEW PROJECTPLASMA A AS A PREDICTOR OF AMYLOID POSITIVITY IN ALZHEIMER'S DISEASEINTENDED TO IDENTIFY SIMPLE, EFFECTIVE TESTS TO DETECT EARLY ALZHEIMER'S DISEASE, PAVING THE WAY FOR POTENTIAL TREATMENTS THAT COULD STOP THE DISORDER BEFORE IT HAS SERIOUSLY DAMAGED THE BRAIN. THE NEW FNIH PROJECT BRINGS TOGETHER GOVERNMENT, ACADEMIC, NOT-FOR-PROFIT AND INDUSTRY EXPERTS TO COMPARE SIX DIFFERENT POTENTIAL PLATFORMS TO MEASURE BETA AMYLOID, OR ABETA, IN A PERSON'S BODY. DEPOSITS OF ABETA IN THE BRAIN CAUSE PLAQUES BETWEEN NERVE CELLS AND ARE THOUGHT TO PLAY A ROLE IN ALZHEIMER'S DISEASE. THE TESTS UNDER EVALUATION MEASURE LEVELS OF ABETA IN PLASMA, REQUIRING ONLY A SIMPLE BLOOD DRAW. THE GOAL OF THE PARTNERSHIP IS TO DETERMINE WHICH PLATFORMS FOR MEASURING ABETA IN BLOOD PLASMA CAN ACCURATELY PREDICT THE PRESENCE OF BETA AMYLOID IN THE BRAIN. AN ABETA BLOOD TEST COULD REPLACE CURRENT TOOLS FOR MEASURING BETA AMYLOID, SUCH AS PET SCANS OR TESTING OF CEREBROSPINAL FLUID, WHICH CAN BE INVASIVE, EXPENSIVE AND PAINFUL. THIS WOULD IMMEDIATELY MAKE CLINICAL TRIALS FOR ALZHEIMER'S DISEASE PREVENTION AND TREATMENT EASIER ON RESEARCHERS AND TRIAL VOLUNTEERS. OVER THE LONGER TERM, THE TEST COULD SPEED THE SEARCH FOR NEW TREATMENTS THAT TARGET THE DISEASE IN ITS EARLIEST STAGESSPARING MILLIONS OF AMERICANS FROM THE RISK OF IRREVERSIBLE BRAIN DAMAGE. |
| FORM 990, PART VI, SECTION A, LINE 1 |
THE BOARD HAS AN EXECUTIVE COMMITTEE, WHICH CAN MAKE DECISIONS ON BEHALF OF THE BOARD (WITH SOME EXCEPTIONS) IN BETWEEN BOARD MEETINGS. |
| FORM 990, PART VI, SECTION B, LINE 11B |
PRIOR TO THE SUBMISSION OF THE FOUNDATION FOR NIH'S FORM 990 TO THE INTERNAL REVENUE SERVICE, EACH VOTING MEMBER OF THE BOARD OF DIRECTORS SHALL BE PROVIDED WITH A COPY OF THE DRAFT FORM 990 AS APPROVED BY THE CHIEF FINANCIAL OFFICER. |
| FORM 990, PART VI, SECTION B, LINE 12C |
DIRECTORS, OFFICERS AND EMPLOYEES ARE REQUIRED TO ANNUALLY SIGN A STATEMENT WHICH AFFIRMS THAT THEY HAVE: O RECEIVED A COPY OF THE CONFLICT OF INTEREST POLICY O READ, UNDERSTOOD AND AGREED TO COMPLY WITH THE POLICY O RECEIVED AND REVIEWED A LISTING OF CORPORATE AND FOUNDATION DONORS, CONTRACTORS, VENDORS, GRANTEES, PRINCIPAL INVESTIGATORS AND FINANCIAL INSTITUTIONS WITH WHOM THE FNIH HAS A CURRENT RELATIONSHIP O NO ACTUAL OR APPARENT CONFLICTS OF INTEREST OTHER THAN THOSE DISCLOSED IN THE STATEMENT. THEY MUST ALSO MAKE CERTAIN NOTIFICATIONS IN PARTICULAR CIRCUMSTANCES. THE CONFLICT OF INTEREST POLICY ALSO HAS MECHANISMS FOR HANDLING SUCH CONFLICTS. |
| FORM 990, PART VI, SECTION B, LINE 15 |
THE COMPENSATION COMMITTEE OF THE BOARD REVIEWED AND CONCURRED WITH THE PRESIDENT AND EXECUTIVE DIRECTOR'S DECISIONS ESTABLISHING AND ADJUSTING THE SENIOR EXECUTIVE TEAM'S ANNUAL SALARIES AND RELATED COMPENSATION DECISIONS. THE COMPENSATION COMMITTEE ALSO APPROVED THE COMPENSATION LEVEL OF THE PRESIDENT AND EXECUTIVE DIRECTOR AND RELATED COMPENSATION DECISIONS. |
| FORM 990, PART VI, SECTION C, LINE 19 |
ALL SUCH DOCUMENTS ARE AVAILABLE UPON REQUEST. IN ADDITION, THE GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS ARE AVAILABLE ON THE FNIH WEBSITE. |
| FORM 990, PART VII, SECTION A: |
DONALD M. HILL AND KEVIN A. KLOCK WERE KEY EMPLOYEES THROUGH SEPTEMBER 2020 AND WERE RECLASSIFIED AS OFFICERS STARTING OCTOBER 2020. |
| FORM 990, PART XII, LINE 2C: |
PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. |
Attach to Form 990 or 990-EZ.